Investor Presentaiton
Top-tier talent
Differentiated process
Scalable platform
Proprietary data driven insights drive conviction
Claims analysis
OHCM market independently verified
(diagnosed patients in thousands)
88
88
Significant market building opportunity
(subsequent MD visits for patients diagnosed in 2018)
80-100
100%
>50% with
initial HCM
diagnosis do
not return for
HCM care in
future years
Result
Strategy & Analytics provided
conviction in the novel HCM
commercial opportunity
Expanded Cytokinetics partnership
with up to $450m in funding
Aficamten synthetic royalty for
up to $150m
Commercial launch capital of up
40%
33%
19%
to $300m
Royalty Pharma
(1)
Bristol Myers
2018
2019
2020
2021
OHCM: Obstructive Hypertrophic Cardiomyopathy; MD: medical doctor
Bristol Myers company presentation, October 5, 2020.
ROYALTY PHARMA
1.
60
60View entire presentation